PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS
Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?
Best Penny Stocks To Buy Under $1.25? 3 To Watch Now
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for August 23rd
Penny Stocks To Buy This Week? 4 To Watch Under $5
Pieris (PIRS) Up On Receiving Milestone Payment From Partner
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
New Strong Buy Stocks for August 16th
Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
3 Doomed Biotech Stocks Destined for Disaster
Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
Pieris Pharmaceuticals: Expanding Elarekibep (AZD1402) Trial Finally Has Active And Completed Sites
Best Penny Stocks To Buy Now? 7 Under $1 To Watch
Best Penny Stocks to Buy? 3 Under $1 To Watch Before Next Week
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
Pieris Pharmaceuticals, Inc. (PIRS) Q3 2022 Earnings Call Transcript
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS)
Pieris Pharmaceuticals, Inc (PIRS) CEO Stephen S. Yoder on Q1 2022 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
This Pharmaceutical Stock Could Be Your Lottery Ticket
This Pharmaceutical Stock Could Bank Billions Soon